Role of genomics in identifying new targets for cancer therapy.

Sarah L. Anzick, Jeffrey M. Trent

Research output: Contribution to journalArticle

Abstract

The detailed map of the human genome can potentially transform future cancer therapy by merging genomics with pharmacology, thereby identifying which patients will benefit from specific therapeutic agents. Single-nucleotide polymorphisms (SNPs) provide a valuable tool for this pharmacogenetic approach to cancer therapy. The discovery of SNPs as disease markers may facilitate identification of populations at increased risk for certain cancers. In addition, SNP genetic screening may facilitate administration of appropriate treatment modalities or reveal specific genetic profiles that have importance in drug efficacy and toxicity. In addition to SNP analysis, DNA and tissue microarray analyses have the potential to transform the future of cancer therapy. For example, DNA microarrays may improve tumor classification systems as well as provide a molecular level dissection of global gene expression changes that occur in carcinogenesis. Tissue microarrays would allow one to verify candidate genes, identified from DNA microarrays, against archival tumor specimens with known clinical outcome. In addition, both microarray technologies may be combined to rapidly validate gene targets. We will review and discuss these state-of-the-art technologies including data suggesting that the combined use of these high throughput technologies will facilitate our understanding of the genetic complexities inherent in cancer and will revolutionize cancer therapy.

Original languageEnglish (US)
Pages (from-to)7-13
Number of pages7
JournalOncology
Volume16
Issue number5 Suppl 4
StatePublished - May 2002
Externally publishedYes

Fingerprint

Genomics
Single Nucleotide Polymorphism
Neoplasms
Oligonucleotide Array Sequence Analysis
Therapeutics
Technology
Tissue Array Analysis
Pharmacogenetics
Genetic Testing
Human Genome
Drug-Related Side Effects and Adverse Reactions
Genes
Dissection
Carcinogenesis
Pharmacology
Gene Expression

ASJC Scopus subject areas

  • Oncology

Cite this

Anzick, S. L., & Trent, J. M. (2002). Role of genomics in identifying new targets for cancer therapy. Oncology, 16(5 Suppl 4), 7-13.

Role of genomics in identifying new targets for cancer therapy. / Anzick, Sarah L.; Trent, Jeffrey M.

In: Oncology, Vol. 16, No. 5 Suppl 4, 05.2002, p. 7-13.

Research output: Contribution to journalArticle

Anzick, SL & Trent, JM 2002, 'Role of genomics in identifying new targets for cancer therapy.', Oncology, vol. 16, no. 5 Suppl 4, pp. 7-13.
Anzick SL, Trent JM. Role of genomics in identifying new targets for cancer therapy. Oncology. 2002 May;16(5 Suppl 4):7-13.
Anzick, Sarah L. ; Trent, Jeffrey M. / Role of genomics in identifying new targets for cancer therapy. In: Oncology. 2002 ; Vol. 16, No. 5 Suppl 4. pp. 7-13.
@article{320247f0101e40f2a4424672c16e5cb2,
title = "Role of genomics in identifying new targets for cancer therapy.",
abstract = "The detailed map of the human genome can potentially transform future cancer therapy by merging genomics with pharmacology, thereby identifying which patients will benefit from specific therapeutic agents. Single-nucleotide polymorphisms (SNPs) provide a valuable tool for this pharmacogenetic approach to cancer therapy. The discovery of SNPs as disease markers may facilitate identification of populations at increased risk for certain cancers. In addition, SNP genetic screening may facilitate administration of appropriate treatment modalities or reveal specific genetic profiles that have importance in drug efficacy and toxicity. In addition to SNP analysis, DNA and tissue microarray analyses have the potential to transform the future of cancer therapy. For example, DNA microarrays may improve tumor classification systems as well as provide a molecular level dissection of global gene expression changes that occur in carcinogenesis. Tissue microarrays would allow one to verify candidate genes, identified from DNA microarrays, against archival tumor specimens with known clinical outcome. In addition, both microarray technologies may be combined to rapidly validate gene targets. We will review and discuss these state-of-the-art technologies including data suggesting that the combined use of these high throughput technologies will facilitate our understanding of the genetic complexities inherent in cancer and will revolutionize cancer therapy.",
author = "Anzick, {Sarah L.} and Trent, {Jeffrey M.}",
year = "2002",
month = "5",
language = "English (US)",
volume = "16",
pages = "7--13",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "5 Suppl 4",

}

TY - JOUR

T1 - Role of genomics in identifying new targets for cancer therapy.

AU - Anzick, Sarah L.

AU - Trent, Jeffrey M.

PY - 2002/5

Y1 - 2002/5

N2 - The detailed map of the human genome can potentially transform future cancer therapy by merging genomics with pharmacology, thereby identifying which patients will benefit from specific therapeutic agents. Single-nucleotide polymorphisms (SNPs) provide a valuable tool for this pharmacogenetic approach to cancer therapy. The discovery of SNPs as disease markers may facilitate identification of populations at increased risk for certain cancers. In addition, SNP genetic screening may facilitate administration of appropriate treatment modalities or reveal specific genetic profiles that have importance in drug efficacy and toxicity. In addition to SNP analysis, DNA and tissue microarray analyses have the potential to transform the future of cancer therapy. For example, DNA microarrays may improve tumor classification systems as well as provide a molecular level dissection of global gene expression changes that occur in carcinogenesis. Tissue microarrays would allow one to verify candidate genes, identified from DNA microarrays, against archival tumor specimens with known clinical outcome. In addition, both microarray technologies may be combined to rapidly validate gene targets. We will review and discuss these state-of-the-art technologies including data suggesting that the combined use of these high throughput technologies will facilitate our understanding of the genetic complexities inherent in cancer and will revolutionize cancer therapy.

AB - The detailed map of the human genome can potentially transform future cancer therapy by merging genomics with pharmacology, thereby identifying which patients will benefit from specific therapeutic agents. Single-nucleotide polymorphisms (SNPs) provide a valuable tool for this pharmacogenetic approach to cancer therapy. The discovery of SNPs as disease markers may facilitate identification of populations at increased risk for certain cancers. In addition, SNP genetic screening may facilitate administration of appropriate treatment modalities or reveal specific genetic profiles that have importance in drug efficacy and toxicity. In addition to SNP analysis, DNA and tissue microarray analyses have the potential to transform the future of cancer therapy. For example, DNA microarrays may improve tumor classification systems as well as provide a molecular level dissection of global gene expression changes that occur in carcinogenesis. Tissue microarrays would allow one to verify candidate genes, identified from DNA microarrays, against archival tumor specimens with known clinical outcome. In addition, both microarray technologies may be combined to rapidly validate gene targets. We will review and discuss these state-of-the-art technologies including data suggesting that the combined use of these high throughput technologies will facilitate our understanding of the genetic complexities inherent in cancer and will revolutionize cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=0036560166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036560166&partnerID=8YFLogxK

M3 - Article

C2 - 12102580

AN - SCOPUS:0036560166

VL - 16

SP - 7

EP - 13

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 5 Suppl 4

ER -